Sunpharma FY26 Annual Earnings Summary

Halol, Mohali, and Dadra facilities remain under FDA warning letters, limiting generic approvals and U.S. supply flexibility.

Potential tariffs on patented drug imports into the US could impact Sun Pharma's innovative portfolio, though generics are expected to be excluded.

US generic sales declined due to additional competition on certain products, and recovery depends on resolving manufacturing compliance issues at several sites.

Generic lenalidomide continues to face pricing erosion, impacting U.S. generic business performance.

New product launches may face slower-than-expected formulary coverage or market adoption, impacting revenue ramp.

While currently exempt, pharma may face tariffs after the 232 investigation, which could impact U.S. business margins.

Lenalidomide sales have dropped YoY and are expected to be minimal in the second half, impacting US generics revenue.

ETR increased to 24.7% from 15.8% YoY due to expiry of tax benefits, expected to hover around 25%, pressuring net profit growth.

Stagnation in prescriptions for existing targeted treatments could hinder Leqselvi's uptake, though management expects market growth.

CMS proposed pricing models could impact US revenues; management declined to share mitigation strategies, citing commercial sensitivity.

Effective tax rate rose to ~25% from ~15% last year, dampening PAT growth relative to EBITDA growth; expected to remain in that range.

Management noted that milestone income of $55 million in Q3 may not recur in future quarters, potentially impacting revenue comparability.